10-K: OptimizeRx Reports Increased Revenue but Faces Net Loss in 2024; Names New CEO

OptimizeRx's 2024 10-K filing reveals a revenue increase driven by acquisitions and DAAP sales, but also highlights a net loss and ongoing efforts to improve financial controls.

Summary

• OptimizeRx's 10-K filing for the year ended December 31, 2024, indicates a 29% increase in net revenue to $92.1 million, compared to $71.5 million in 2023.
• The revenue growth was primarily driven by the acquisition of Medicx Health and increased sales related to the Dynamic Audience Activation Platform (DAAP).
• However, the company reported a net loss of $20.1 million for 2024, compared to a net loss of $17.6 million in 2023.
• The company is focusing on becoming a Rule of 40 company, aiming for a combined annual revenue growth rate and EBITDA margin of 40% or higher.
• Stephen L. Silvestro was appointed as the new Chief Executive Officer on March 10, 2025.
• A material weakness in internal control over financial reporting was identified, and remediation efforts are ongoing.
• The company is transitioning DAAP customers to a subscription-based model to improve EBITDA margins and revenue predictability.
• The company's top five customers accounted for approximately 49% of revenue in 2024.
• The company's Term Loan bears interest at a variable rate, which was 13.3% at December 31, 2024.
• The company is subject to market risks arising from changes in interest rates which relate primarily to the Term Loan, which is variable rate debt.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue increased, the company experienced a net loss and identified a material weakness in internal controls. The appointment of a new CEO and strategic focus on becoming a Rule of 40 company offer some positive outlook, but the financial challenges and control issues temper the overall sentiment.

Positives

• Net revenue increased by 29% to $92.1 million.
• The acquisition of Medicx Health expanded the company's capabilities.
• The company is focusing on a strategy to become a Rule of 40 company.
• Net revenue retention rate increased to 121% in 2024.
• Revenue per average full-time employee increased to $701,000.
• The company is transitioning DAAP customers to a subscription-based model for data services.

Negatives

• The company reported a net loss of $20.1 million in 2024.
• A material weakness in internal control over financial reporting was identified.
• The company is dependent on a concentrated group of customers.
• The company's Term Loan bears interest at a variable rate, exposing it to interest rate risk.
• The company recorded impairment charges, related to goodwill, of approximately $7.5 million.

Risks

• The company may not be able to achieve or sustain profitability.
• The company may need to raise additional capital and may not be able to do so on favorable terms.
• Restrictions in the Term Loan could adversely affect the business.
• Seasonal trends in the pharmaceutical brand marketing industry could affect operating results.
• Failure to comply with healthcare industry laws and regulations could adversely affect the business.
• Cybersecurity incidents could disrupt business operations and result in the loss of critical information.
• The company may be unable to manage growth effectively.
• Interest rate increases may adversely affect the company's financial condition.
• Geopolitical events may affect the business and customer base.
• Conflicting views on environmental, social and governance matters may have a negative impact on the business.

Future Outlook

The company believes that funds generated from operations, together with existing cash and cash equivalents, will be sufficient to finance current operations and planned growth for the next twelve months and beyond.

Management Comments

• A core aspect of our new value creation strategy will be to drive towards being recognized as a Rule of 40 company within the next several years such that our combined annual revenue growth rate and EBITDA margin are 40% or higher.
• As we drive towards this ambitious financial goal, we plan to develop a re-occurring revenue component to our business as we look to convert our DAAP customers to a subscription-based model for the data component of our offerings.

Industry Context

The life sciences industry is characterized by rapidly advancing science and technologies, intense competition, and a strong emphasis on differentiated products, leading organizations to increasingly turn to technology solutions to support their commercial strategies.

Comparison to Industry Standards

• The document mentions that the total pharmaceutical industry commercial spend in the United States is $30 billion, of which approximately $10 billion is attributable to commercial digital spend.
• The document does not provide specific comparisons to industry standards or comparable companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings, and is not aware of any pending or threatened material legal or administrative proceedings against it.

Related Party Transactions

• Jim Lang, one of our Board Members, is the CEO of Eversana, a leading global provider of services to the life sciences industry, and the company has recognized revenue from contracts engaged with Eversana.
• William J. Febbo, former Chief Executive Officer of OptimizeRx was appointed to LifeMDs board of directors during Q2 2023, and the company has recognized revenue from contracts engaged with LifeMD.

Stakeholder Impact

• Shareholders: The company's financial performance and strategic direction will impact shareholder value.
• Employees: Changes in management and strategic focus may affect employee roles and opportunities.
• Customers: The company's ability to deliver effective solutions will impact customer satisfaction and business relationships.
• Creditors: The company's financial performance will impact its ability to meet debt obligations.

Next Steps

• The company plans to transition DAAP customers to a subscription-based model.
• The company will continue to implement and improve its operating and financial systems and controls.
• The company will continue to remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

OptimizeRx, revenue, EBITDA, Medicx Health, DAAP, financial results, internal control, pharmaceutical marketing, healthcare technology, Rule of 40